PT  - JOURNAL ARTICLE
AU  - Xiaoteng Cui
AU  - Yunfei Wang
AU  - Junhu Zhou
AU  - Qixue Wang
AU  - Chunsheng Kang
TI  - Expert opinion on translational research for advanced glioblastoma treatment
AID  - 10.20892/j.issn.2095-3941.2023.0012
DP  - 2023 Apr 25
TA  - Cancer Biology & Medicine
PG  - 20230012
4099  - http://www.cancerbiomed.org/content/early/2023/04/25/j.issn.2095-3941.2023.0012.short
4100  - http://www.cancerbiomed.org/content/early/2023/04/25/j.issn.2095-3941.2023.0012.full
AB  - Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern, rapid progression, and poor prognosis. Many antitumor drugs are not ideal for the treatment of gliomas due to the blood-brain barrier. Temozolomide (TMZ) is a DNA alkylating agent that can cross the blood-brain barrier. As the only first-line chemotherapeutic drug for malignant gliomas at present, TMZ is widely utilized to provide a survival benefit; however, some patients are inherently insensitive to TMZ. In addition, patients could develop acquired resistance during TMZ treatment, which limits antitumor efficacy. To clarify the mechanism underlying TMZ resistance, numerous studies have provided multilevel solutions, such as improving the effective concentration of TMZ in tumors and developing novel small molecule drugs. This review discusses the in-depth mechanisms underlying TMZ drug resistance, thus aiming to provide possibilities for the establishment of personalized therapeutic strategies against malignant gliomas and the accelerated development and transformation of new targeted drugs.